Annovis Bio (ANVS) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annovis Bio (ANVS) has outperformed Werewolf Therapeutics (HOWL) over the past year, losing 48.5% versus a loss of 51.6%. Over five years, HOWL leads with a -94.7% price change compared with -95.8% for ANVS. Annovis Bio is the larger company by market cap ($51.6 million vs $47.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | HOWL |
|---|---|---|
| Share price | $1.21 | $0.9796 |
| Market cap | $51.64M | $47.61M |
| 1-day change | +3.42% | +7.65% |
| YTD return | -66.18% | +43.53% |
| 1-year return | -48.46% | -51.60% |
| 5-year return | -95.82% | -94.67% |
| EPS (TTM) | $-1.75 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $1.85 |
| 52-week low | $1.04 | $0.27 |
| Distance from 52-week high | -78.00% | -47.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +767.77% | +614.58% |
| Average volume | 884.63K | 6.80M |
| Shares outstanding | 42.68M | 48.60M |
| Employees | 7 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
ANVS vs HOWL FAQ
Which is bigger, Annovis Bio or Werewolf Therapeutics?
Annovis Bio (ANVS) is larger, with a market capitalization of $51.64M compared with $47.61M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, ANVS or HOWL?
ANVS returned -48.46% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.